NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The site is advancing research on cardiovascular disease, targeting conditions that affect the heart and blood vessels.
- Acute myocardial infarction
- Atrial fibrillation
- Heart failure
- Atherosclerotic cardiovascular disease
- Stroke prevention
Ongoing studies aim to evaluate new therapeutic options, improve long‑term safety, and reduce major cardiovascular events for patients at risk.
Immune System Diseases
Research at this centre includes innovative work on autoimmune disorders that impair neuromuscular and central nervous system function.
- Generalized Myasthenia Gravis
- Ocular Myasthenia Gravis
- Relapsing Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Progressive Forms of Multiple Sclerosis
These trials focus on testing novel biologics and immune‑modulating agents to improve disease control and quality of life.
Musculoskeletal Diseases
The facility conducts studies on musculoskeletal conditions that cause pain, weakness, and functional limitation.
- Chronic non‑specific low back pain
- Upper‑limb spasticity after stroke
- Distal sensory polyneuropathy
- Botulinum toxin injection for spasticity
- Muscle‑related pain syndromes
The goal is to assess pain relief, functional improvement, and safety of new analgesic and injectable therapies.
Nervous System Diseases
A major focus is on neurodegenerative and cognitive disorders, seeking treatments that modify disease progression.
- Alzheimer disease
- Early Alzheimer’s disease with inflammatory biomarkers
- Mild cognitive impairment
- Dementia of the Alzheimer’s type
- Tauopathies
- Neurodegenerative diseases
- Multiple Sclerosis (relapsing and progressive)
Studies evaluate disease‑modifying agents, cognitive outcomes, and biomarker changes to slow decline and improve daily functioning.
Nutritional and Metabolic Diseases
The centre also investigates metabolic and nutritional disorders that impact weight and systemic health.
- Obesity
- Overweight
- Metabolic syndrome
- Diabetic peripheral neuropathic pain
- Weight‑management therapies
Clinical work aims to test new weight‑loss agents and assess their impact on metabolic parameters and safety profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 69 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 68 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Tg Therapeutics Inc.2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.7trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 69 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paracetamol | 5 | Unknown | 2024-01-16 | 2025-06-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.